8.86%C 6.45 22.20%F 2.55 5.20%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
Geron Corp. the developer of biopharmaceuticals for cancer and chronic degenerative diseases treatments said U.S. regulators put a clinical hold to its investigational cell therapy for spinal cord injury.
By putting the GRNOPC1 on hold the Food and Drug Administration suspended development of the drug . The group expressed its disappointment since the submission has been in development for four years and has been based on discussions with regulators.
"We have not yet received a letter from the FDA explaining the decision to place the submission on hold, so we are unable to comment specifically," said Thomas Okarma, Executive Officer in a statement.
Geron shares fell as much as 19.39 percent to $3.95 on Nasdaq closing trading on Wednesday.
Major U.S. stock indexes slumped further south midday Monday, further extending this morning's hefty losses which erased last week's f...
China markets opened lower on Tuesday morning as the investors' confidence hit by the signals that global recession are deepening.
A special Iraqi court has sentenced Saddam Hussein's cousin "Chemical Ali" al-Majid to death for his role in the 1991 suppression of a Shiite upr...
|
Get your next web design project done with our los angeles web design team - Best web design with great price.
Building your business and corporate credit for your small business.
Split Big Profits! You Find it & We Fund it! Co-Own Or Cash Out! Get Free Info Kit Now!
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
